The progression of inflammation parallels the dermal angiogenesis in a Keratin 14 IL-4-Transgenic model of atopic dermatitis

Microcirculation

Volumn 15, Issue 1, 2008, Pages 49-64

  Chen, Lin ^a   Marble, Deborah J ^a   Agha, Rania ^a   Peterson, Jennifer D ^a   Becker, Robert P ^a   Jin, Tianquan ^a   Li, Jianxun ^a   Chan, Lawrence S ^a,b  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b JESSE BROWN VA MEDICAL CENTER   (United States)

Author keywords

Angiogenesis; Animal model; Atopic dermatitis; Inflammation; VEGF

Indexed keywords

ANGIOPOIETIN 1; ANGIOPOIETIN 2; ANGIOPOIETIN RECEPTOR; CD31 ANTIGEN; CYTOKERATIN 14; GAMMA INTERFERON; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; GUANOSINE TRIPHOSPHATASE; INTERLEUKIN 4; INTERLEUKIN 6; MESSENGER RNA; VASCULAR ENDOTHELIAL CADHERIN; VASCULOTROPIN A; VASCULOTROPIN B; VASCULOTROPIN C; VASCULOTROPIN D; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 3;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATOPIC DERMATITIS; BLOOD VESSEL DIAMETER; BLOOD VESSEL PERMEABILITY; COMPUTER ANALYSIS; CONTROLLED STUDY; DISEASE COURSE; DISEASE MODEL; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMUNOFLUORESCENCE; MICROVASCULATURE; MOUSE; NONHUMAN; PATHOGENESIS; PHOTOMETRY; PRIORITY JOURNAL; PROTEIN SYNTHESIS; QUANTITATIVE ANALYSIS; SKIN BLOOD VESSEL; TRANSGENIC MOUSE; UPREGULATION;

ANGIOTENSIN I; ANGIOTENSIN II; ANIMALS; ANTIGENS, CD; CADHERINS; CELLS, CULTURED; DERMATITIS, ATOPIC; DERMIS; DISEASE MODELS, ANIMAL; GTP-BINDING PROTEINS; INTERFERON TYPE II; INTERLEUKIN-4; INTERLEUKIN-6; KERATIN-14; KERATINOCYTES; MICE; MICE, TRANSGENIC; MICROCIRCULATION; NEOVASCULARIZATION, PATHOLOGIC; UP-REGULATION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

ANIMALIA; MUS MUSCULUS;

EID: 38049161744     PISSN: 10739688     EISSN: 15498719     Source Type: Journal    
DOI: 10.1080/10739680701418416     Document Type: Article

References (64)

1. Folkman, J. (2002) Role of angiogenesis in tumor growth and metastasis. Semin Oncol, 29, pp. 15-18.
2. Shih, T. and Lindley, C. (2006) Bevacizumab: An angiogenesis inhibitor for the treatment of solid malignancies. Clin Ther, 28, pp. 1779-1802.
3. Escudier, B., Eisen, T., Stadler, W. M., Szczylik, C., Oudard, S., Siebels, M., Negrier, S., Chevreau, C., Solska, E., Desai, A. A., Rolland, F., Demkow, T., Hutson, T. E., Gore, M., Freeman, S., Schwartz, B., Shan, M., Simantov, R. and Bukowski, R. M. (2007) Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med, 356, pp. 125-134.
4. Motzer, R. J., Michaelson, M. D., Redman, B. G., Hudes, G. R., Wilding, G., Figlin, R. A., Ginsberg, M. S., Kim, S. T., Baum, C. M., De Primo, S. E., Li, J. Z., Bello, C. L., Theuer, C. P., George, D. J. and Rini, B. I. (2006) Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol, 24, pp. 16-24.
5. Feldman, D. R. and Motzer, R. J. (2006) Novel targets and therapies for metastatic renal cell carcinoma. Oncology (Williston Park), 20, pp. 1745-1753.
6. Bagli, E., Xagorari, A., Papetropoulos, A., Murphy, C. and Fotsis, T. (2004) Angiogenesis in inflammation. Autoimmun Rev, 3, p. S26.
7. Brennen, W. N., Cooper, C. R., Capitosti, S., Brown, M. L. and Sikes, R. A. (2004) Thalidomide and analogues: Current proposed mechanisms and therapeutic usage. Clin Prostate Cancer, 3, pp. 54-61.
8. Du, W., Hattori, Y., Hashiguchi, A., Kondoh, K., Hozumi, N., Ikeda, Y., Sakamoto, M., Hata, J. and Yamada, T. (2004) Tumor angiogenesis in the bone marrow of multiple myeloma patients and its alteration by thalidomide treatment. Pathol Int, 54, pp. 285-294.
9. Gately, S. and Li, W. W. (2004) Multiple roles of COX-2 in tumor angiogenesis: A target for antiangiogenic therapy. Semin Oncol, 31, pp. 2-11.
10. Koehne, C. H. and Dubois, R. N. (2004) COX-2 inhibition and colorectal cancer. Semin Oncol, 31, pp. 12-21.
11. Streck, C. J., Zhang, Y., Miyamoto, R., Zhou, J., Ng, C. Y., Nathwani, A. C. and Davidoff, A. M. (2004) Restriction of neuroblastoma angiogenesis and growth by interferon-alpha/beta. Surgery, 136, pp. 183-189.
12. Shishodia, S. and Aggarwal, B. B. (2004) Cyclooxygenase (COX)-2 inhibitor celecoxib abrogates activation of cigarette smoke-induced nuclear factor (NF)-kappaB by suppressing activation of IkappaBalpha kinase in human non-small cell lung carcinoma: Correlation with suppression of cyclin D1, COX-2, and matrix metalloproteinase-9. Cancer Res, 64, pp. 5004-5012.
13. Inai, T., Mancuso, M., Hashizume, H., Baffert, F., Haskell, A., Baluk, P., Hu-Lowe, D. D., Shalinsky, D. R., Thurston, G., Yancopoulos, G. D. and McDonald, D. M. (2004) Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts. Am J Pathol, 165, pp. 35-52.
14. Grosios, K., Wood, J., Esser, R., Raychaudhuri, A. and Dawson, J. (2004) Angiogenesis inhibition by the novel VEGF receptor tyrosine kinase inhibitor, PTK787/ZK222584, causes significant anti-arthritic effects in models of rheumatoid arthritis. Inflamm Res, 53, pp. 133-142.
15. Leung, D. Y. and Bieber, T. (2003) Atopic dermatitis. Lancet, 361, pp. 151-160.
16. Leung, D. Y., Boguniewicz, M., Howell, M. D., Nomura, I. and Hamid, Q. A. (2004) New insights into atopic dermatitis. J Clin Invest, 113, pp. 651-657.
17. Agha-Majzoub, R., Becker, R. P., Schraufnagel, D. E. and Chan, L. S. (2005) Angiogenesis: The major abnormality of the keratin-14 IL-4 transgenic mouse model of atopic dermatitis. Microcirculation, 12, pp. 455-476.
18. Chan, L. S., Robinson, N. and Xu, L. (2001) Expression of interleukin-4 in the epidermis of transgenic mice results in a pruritic inflammatory skin disease: An experimental animal model to study atopic dermatitis. J Invest Dermatol, 117, pp. 977-983.
19. Chen, L., Martinez, O., Venkataramani, P., Lin, S. X., Prabhakar, B. S. and Chan, L. S. (2005) Correlation of disease evolution with progressive inflammatory cell activation and migration in the IL-4 transgenic mouse model of atopic dermatitis. Clin Exp Immunol, 139, pp. 189-201.
20. Chen, L., Lin, S. X., Overbergh, L., Mathieu, C. and Chan, L. S. (2005) The disease progression in the keratin 14 IL-4-transgenic mouse model of atopic dermatitis parallels the upregulations of B cell activation molecules, proliferation, and surface and serum IgE. Clin Exp Immunol, 142, pp. 21-30.
21. Chen, L., Martinez, O., Overbergh, L., Mathieu, C., Prabhakar, B. S. and Chan, L. S. (2004) Early up-regulation of Th2 cytokines and late surge of Th1 cytokines in an atopic dermatitis model. Clin Exp Immunol, 138, pp. 375-387.
22. Zhang, Y., Matsuo, H. and Morita, E. (2006) Increased production of vascular endothelial growth factor in the lesions of atopic dermatitis. Arch Dermatol Res, 297, pp. 425-429.
23. Shih, S. C., Robinson, G. S., Perruzzi, C. A., Calvo, A., Desai, K., Green, J. E., Ali, I. U., Smith, L. E. and Senger, D. R. (2002) Molecular profiling of angiogenesis markers. Am J Pathol, 161, pp. 35-41.
24. Voros, G., Maquoi, E., Demeulemeester, D., Clerx, N., Collen, D. and Lijnen, H. R. (2005) Modulation of angiogenesis during adipose tissue development in murine models of obesity. Endocrinology, 146, pp. 4545-4554.
25. Shih, S. C., Ju, M., Liu, N. and Smith, L. E. (2003) Selective stimulation of VEGFR-1 prevents oxygen-induced retinal vascular degeneration in retinopathy of prematurity. J Clin Invest, 112, pp. 50-57.
26. Thijssen, V. L., Brandwijk, R. J., Dings, R. P. and Griffioen, A. W. (2004) Angiogenesis gene expression profiling in xenograft models to study cellular interactions. Exp Cell Res, 299, pp. 286-293.
27. Giulietti, A., Overbergh, L., Valckx, D., Decallonne, B., Bouillon, R. and Mathieu, C. (2001) An overview of real-time quantitative PCR: applications to quantify cytokine gene expression. Methods, 25, pp. 386-401.
28. Hulthen, U. L., Cao, Z., Rumble, J. R., Cooper, M. E. and Johnston, C. I. (1996) Vascular hypertrophy and albumin permeability in a rat model combining hypertension and diabetes mellitus. Effects of calcium antagonism, angiotensin converting enzyme inhibition, and angiotensin II-AT1-receptor blockade. Am J Hypertens, 9, pp. 895-901.
29. Ruhrberg, C. (2003) Growing and shaping the vascular tree: Multiple roles for VEGF. Bioessays, 25, pp. 1052-1060.
30. Yancopoulos, G. D., Davis, S., Gale, N. W., Rudge, J. S., Wiegand, S. J. and Holash, J. (2000) Vascular-specific growth factors and blood vessel formation. Nature, 407, pp. 242-248.
31. Carmeliet, P., Ferreira, V., Breier, G., Pollefeyt, S., Kieckens, L., Gertsenstein, M., Fahrig, M., Vandenhoeck, A., Harpal, K., Eberhardt, C., Declercq, C., Pawling, J., Moons, L., Collen, D., Risau, W. and Nagy, A. (1996) Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature, 380, pp. 435-439.
32. Lee, S. S., Joo, Y. S., Kim, W. U., Min, D. J., Min, J. K., Park, S. H., Cho, C. S. and Kim, H. Y. (2001) Vascular endothelial growth factor levels in the serum and synovial fluid of patients with rheumatoid arthritis. Clin Exp Rheumatol, 19, pp. 321-324.
33. Harada, M., Mitsuyama, K., Yoshida, H., Sakisaka, S., Taniguchi, E., Kawaguchi, T., Ariyoshi, M., Saiki, T., Sakamoto, M., Nagata, K., Sata, M., Matsuo, K. and Tanikawa, K. (1998) Vascular endothelial growth factor in patients with rheumatoid arthritis. Scand J Rheumatol, 27, pp. 377-380.
34. Detmar, M., Yeo, K. T., Nagy, J. A., Van de Water, L., Brown, L. F., Berse, B., Elicker, B. M., Ledbetter, S. and Dvorak, H. F. (1995) Keratinocyte-derived vascular permeability factor (vascular endothelial growth factor) is a potent mitogen for dermal microvascular endothelial cells. J Invest Dermatol, 105, pp. 44-50.
35. Trompezinski, S., Denis, A., Vinche, A., Schmitt, D. and Viac, J. (2002) IL-4 and interferon-gamma differentially modulate vascular endothelial growth factor release from normal human keratinocytes and fibroblasts. Exp Dermatol, 11, pp. 224-231.
36. Chen, L., Lin, S. X., Agha-Majzoub, R., Overbergh, L., Mathieu, C. and Chan, L. S. (2006) CCL27 is a critical factor for the development of atopic dermatitis in the keratin-14-IL-4-transgenic mouse model. Int Immunol, 18, pp. 1233-1242.
37. Maisonpierre, P. C., Suri, C., Jones, P. F., Bartunkova, S., Wiegand, S. J., Radziejewski, C., Compton, D., McClain, J., Aldrich, T. H., Papadopoulos, N., Daly, T. J., Davis, S., Sato, T. N. and Yancopoulos, G. D. (1997) Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science, 277, pp. 55-60.
38. Guenzi, E., Topolt, K., Cornali, E., Lubeseder-Martellato, C., Jorg, A., Matzen, K., Zietz, C., Kremmer, E., Nappi, F., Schwemmle, M., Hohenadl, C., Barillari, G., Tschachler, E., Monini, P., Ensoli, B. and Sturzl, M. (2001) The helical domain of GBP-1 mediates the inhibition of endothelial cell proliferation by inflammatory cytokines. Embo J, 20, pp. 5568-5577.
39. Guenzi, E., Topolt, K., Lubeseder-Martellato, C., Jorg, A., Naschberger, E., Benelli, R., Albini, A. and Sturzl, M. (2003) The guanylate binding protein-1 GTPase controls the invasive and angiogenic capability of endothelial cells through inhibition of MMP-1 expression. EMBO J, 22, pp. 3772-3782.
40. Bhushan, M., Young, H. S., Brenchley, P. E. and Griffiths, C. E. (2002) Recent advances in cutaneous angiogenesis. Br J Dermatol, 147, pp. 418-425.
41. Reinders, M. E., Sho, M., Izawa, A., Wang, P., Mukhopadhyay, D., Koss, K. E., Geehan, C. S., Luster, A. D., Sayegh, M. H. and Briscoe, D. M. (2003) Proinflammatory functions of vascular endothelial growth factor in alloimmunity. J Clin Invest, 112, pp. 1655-1665.
42. Xia, Y. P., Li, B., Hylton, D., Detmar, M., Yancopoulos, G. D. and Rudge, J. S. (2003) Transgenic delivery of VEGF to mouse skin leads to an inflammatory condition resembling human psoriasis. Blood, 102, pp. 161-168.
43. Nakamura, M., Abe, Y. and Tokunaga, T. (2002) Pathological significance of vascular endothelial growth factor A isoform expression in human cancer. Pathol Int, 52, pp. 331-339.
44. Frank, S., Hubner, G., Breier, G., Longaker, M. T., Greenhalgh, D. G. and Werner, S. (1995) Regulation of vascular endothelial growth factor expression in cultured keratinocytes: Implications for normal and impaired wound healing. J Biol Chem, 270, pp. 12607-12613.
45. Ancelin, M., Chollet-Martin, S., Herve, M. A., Legrand, C., Benna, J El and Perrot-Applanat, M. (2004) Vascular endothelial growth factor VEGF189 induces human neutrophil chemotaxis in extravascular tissue via an autocrine amplification mechanism. Lab Invest, 84, pp. 502-512.
46. Mor, F., Quintana, F. J. and Cohen, I. R. (2004) Angiogenesis-inflammation cross-talk: Vascular endothelial growth factor is secreted by activated T cells and induces Th1 polarization. J Immunol, 172, pp. 4618-4623.
47. Detmar, M., Brown, L. F., Schon, M. P., Elicker, B. M., Velasco, P., Richard, L., Fukumura, D., Monsky, W., Claffey, K. P. and Jain, R. K. (1998) Increased microvascular density and enhanced leukocyte rolling and adhesion in the skin of VEGF transgenic mice. J Invest Dermatol, 111, pp. 1-6.
48. Dvorak, H. F., Brown, L. F., Detmar, M. and Dvorak, A. M. (1995) Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol, 146, pp. 1029-1039.
49. Holash, J., Wiegand, S. J. and Yancopoulos, G. D. (1999) New model of tumor angiogenesis: Dynamic balance between vessel regression and growth mediated by angiopoietins and VEGF. Oncogene, 18, pp. 5356-5362.
50. Asahara, T., Chen, D., Takahashi, T., Fujikawa, K., Kearney, M., Magner, M., Yancopoulos, G. D. and Isner, J. M. (1998) Tie2 receptor ligands, angiopoietin-1 and angiopoietin-2, modulate VEGF-induced postnatal neovascularization. Circ Res, 83, pp. 233-240.
51. Papapetropoulos, A., Garcia-Cardena, G., Dengler, T. J., Maisonpierre, P. C., Yancopoulos, G. D. and Sessa, W. C. (1999) Direct actions of angiopoietin-1 on human endothelium: Evidence for network stabilization, cell survival, and interaction with other angiogenic growth factors. Lab Invest, 79, pp. 213-223.
52. Sato, T. N., Tozawa, Y., Deutsch, U., Wolburg-Buchholz, K., Fujiwara, Y., Gendron-Maguire, M., Gridley, T., Wolburg, H., Risau, W. and Qin, Y. (1995) Distinct roles of the receptor tyrosine kinases Tie-1 and Tie-2 in blood vessel formation. Nature, 376, pp. 70-74.
53. Teichert-Kuliszewska, K., Maisonpierre, P. C., Jones, N., Campbell, A. I., Master, Z., Bendeck, M. P., Alitalo, K., Dumont, D. J., Yancopoulos, G. D. and Stewart, D. J. (2001) Biological action of angiopoietin-2 in a fibrin matrix model of angiogenesis is associated with activation of Tie2. Cardiovasc Res, 49, pp. 659-670.
54. Kim, I., Kim, J. H., Moon, S. O., Kwak, H. J., Kim, N. G. and Koh, G. Y. (2000) Angiopoietin-2 at high concentration can enhance endothelial cell survival through the phosphatidylinositol 3'-kinase/Akt signal transduction pathway. Oncogene, 19, pp. 4549-4552.
55. Gale, N. W., Thurston, G., Hackett, S. F., Renard, R., Wang, Q., McClain, J., Martin, C., Witte, C., Witte, M. H., Jackson, D., Suri, C., Campochiaro, P. A., Wiegand, S. J. and Yancopoulos, G. D. (2002) Angiopoietin-2 is required for postnatal angiogenesis and lymphatic patterning, and only the latter role is rescued by angiopoietin-1. Dev Cell, 3, pp. 411-423.
56. Hanahan, D. (1997) Signaling vascular morphogenesis and maintenance. Science, 277, pp. 48-50.
57. Thurston, G. (2002) Complementary actions of VEGF and angiopoietin-1 on blood vessel growth and leakage. J Anat, 200, pp. 575-580.
58. Bach, T. L., Barsigian, C., Chalupowicz, D. G., Busler, D., Yaen, C. H., Grant, D. S. and Martinez, J. (1998) VE-Cadherin mediates endothelial cell capillary tube formation in fibrin and collagen gels. Exp Cell Res, 238, pp. 324-334.
59. Gory-Faure, S., Prandini, M. H., Pointu, H., Roullot, V., Pignot-Paintrand, I., Vernet, M. and Huber, P. (1999) Role of vascular endothelial-cadherin in vascular morphogenesis. Development, 126, pp. 2093-2102.
60. Zanetti, A., Lampugnani, M. G., Balconi, G., Breviario, F., Corada, M., Lanfrancone, L. and Dejana, E. (2002) Vascular endothelial growth factor induces SHC association with vascular endothelial cadherin: A potential feedback mechanism to control vascular endothelial growth factor receptor-2 signaling. Arterioscler Thromb Vasc Biol, 22, pp. 617-622.
61. Esser, S., Lampugnani, M. G., Corada, M., Dejana, E. and Risau, W. (1998) Vascular endothelial growth factor induces VE-cadherin tyrosine phosphorylation in endothelial cells. J Cell Sci, 111, pp. 1853-1865.
62. Naschberger, E., Bauer, M. and Sturzl, M. (2005) Human guanylate binding protein-1 (hGBP-1) characterizes and establishes a non-angiogenic endothelial cell activation phenotype in inflammatory diseases. Adv Enzyme Regul, 45, pp. 215-227.
63. Lubeseder-Martellato, C., Guenzi, E., Jorg, A., Topolt, K., Naschberger, E., Kremmer, E., Zietz, C., Tschachler, E., Hutzler, P., Schwemmle, M., Matzen, K., Grimm, T., Ensoli, B. and Sturzl, M. (2002) Guanylate-binding protein-1 expression is selectively induced by inflammatory cytokines and is an activation marker of endothelial cells during inflammatory diseases. Am J Pathol, 161, pp. 1749-1759.
64. Hanahan, D. and Folkman, J. (1996) Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell, 86, pp. 353-364.